Cancer Treatment to get a Novel Immunotherapy Drug Candidate

Release Date: 15-Nov-2020

Researchers have identified a novel drug that is capable of generating an immune response in the body against the cancer cells. The primary aim of the developed drug by the researchers from Cancer Research UK is suppressive ‘regulatory’ immune cells inside a tumour which is further focused to improve the oversll long-term survival rate in the models alone. The investigational drug candidate developed by the researchers has been tested in different mouse models and it is witnessed to deliver promising results in most of the experiments.


The successful outcome related with the investigational drug is estimated to be providing an overall transformation to the entire immunotherapy market as the drug may have potent action against different types of cancers such as melanoma, certain lung cancers, and head and neck cancer. It is observed that there is an important hallmark present on the T regulatory cells called as CD25. The group of researchers inclined towards the respective study were able to design a drug molecule that could bind to different parts of the CD25 protein. The developed drug candidate doesn’t only eliminate the cells that dampens the action of immune response against cancer but also activate cancer killing immune cells. The strategic approach used by the drug is estimated to revolutionize the entire cancer therapeutics market.


As per the researchers, the investigational drug can come out as a stand-out example of an effective therapy that can lead the researchers towards an era that is having less cancer mortality rate when compared with the mortality rate in the past few decades. The investigational drug is estimated to get evaluated in the future against different types of cancers and will finally on the basis of its performance will get approval from the regulatory bodies, thus changing the standard healthcare regimen for millions of patients.

Need custom market research solution? We can help you with that too.